PARP-1 inhibitor (Mitobridge/Syngene)

N/A

Report date: 2025/03/20 10:03:41
NME

Base Information

Drug NamePARP-1 inhibitor (Mitobridge/Syngene)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitors
TargetsPoly (ADP-Ribose) polymerase 1
Therapy Area/IndicationsRenal Insufficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIndia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMitobridge Inc
China Registration ClassN/A

Develop Information

Active CompaniesSyngene International LtdMitobridge Inc
Inactive CompaniesN/A
Active IndicationsRenal Insufficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A